read the full press release here
ALK-positive lung cancer patients take matters into their own hands to fund research with the potential to save their lives
Each of these two-year awards is for up to $200,000, with monies raised by ALK Positive and Lungevity. The three projects selected aim to understand how immunotherapy can be used for ALK-positive patients.
These new projects, which will uncover why immunotherapy has not been successful in treating ALK-positive lung cancer and test new immunotherapy approaches in ALK-positive lung cancer, include:
- Characterization of anti-ALK immunologic responses in ALK-positive NSCLC: Mark Awad, MD, PhD, Dana-Farber Cancer Institute
- Overcoming innate immune resistance in ALK-rearranged lung cancer: Justin Gainor, MD, Massachusetts General Hospital
- Targeting the complement pathway in ALK positive lung cancer: Raphael Nemenoff, PhD, University of Colorado Denver, AMC and DC
